. 2019 Aug 24;8(3):127. doi: 10.3390/antibiotics8030127

Table 2.

Proposed novel metrics for adjustment of antimicrobial use by microbiological burden at each healthcare facility.

Adjusted AU	Formula
APBL	$\frac{A U_{A P B L}}{(\frac{I n c i d e n c e o f P . a e r u g i n o s a a t l o c a l i n s t i t u t i o n}{A v e r a g e o v e r a l l i n c i d e n c e o f P . a e r u g i n o s a i n n e t w o r k})}$
Carbapenems	$\frac{A U_{C a r b a p e n e m s}}{{(\frac{I n c i d e n c e o f E S B L E a t l o c a l i n s t i t u t i o n}{A v e r a g e o v e r a l l i n c i d e n c e o f E S B L E i n n e t w o r k})}^{*}}$
Anti-MRSA agents	$\frac{A U_{A n t i - M R S A a g e n t s}}{(\frac{I n c i d e n c e o f M R S A a t l o c a l i n s t i t u t i o n}{A v e r a g e o v e r a l l i n c i d e n c e o f M R S A i n n e t w o r k})}$
Anti-VRE agents	$\frac{A U_{A n t i - V R E a g e n t s}}{(\frac{I n c i d e n c e o f V R E a t l o c a l i n s t i t u t i o n}{A v e r a g e o v e r a l l i n c i d e n c e o f V R E i n n e t w o r k})}$

Note: AU: antimicrobial use; APBL: antipseudomonal beta-lactams; ESBLE: extended-spectrum beta-lactamase-producing Enterobacteriaceae; MRSA: methicillin-resistant Staphylococcus aureus; VRE: vancomycin-resistant Enterococcus species. * If microbiology laboratories in one or more hospitals in the network do not perform the ESBL screening test, then the incidence of ceftriaxone-resistant Enterobacteriaceae may be used alternatively to calculate adjusted carbapenem utilization in all hospitals in the network.